Peptides are booming. Patients want them. Practitioners are using them. Regulators are scrutinizing them. And Dr. Rick Jacoby believes the debate raises a much bigger question:
Who gets to decide what the future of medicine looks like?
On this episode of Sugar Crush: The Rest of the Story, Dr. Rick and Grok dive back into the rapidly evolving world of peptides, beginning with one of the most talked-about compounds in regenerative medicine: BPC-157.
They explore what peptides are, how these short chains of amino acids act as biological signals, why BPC-157 has attracted so much attention, and the legitimate concerns surrounding sourcing, purity, manufacturing standards, and the limited amount of rigorous human clinical data currently available.
But rather than simply choosing between unrestricted access and prohibition, Dr. Rick proposes another approach: create guardrails, track outcomes, and collect real-world evidence. He makes the case for a national registry that could anonymously follow peptide use, practitioners, products, outcomes, and adverse events—potentially generating a massive pool of data about how these therapies are actually being used.
Podden och tillhörande omslagsbild på den här sidan tillhör
Richard Jacoby. Innehållet i podden är skapat av Richard Jacoby och inte av,
eller tillsammans med, Poddtoppen.
